Please check your internet connection and try again.
# Flupentixol and Melitracen
## Overview
Flupentixol/melitracen is a fixed-dose combination psychotropic. Flupentixol is a thioxanthene antipsychotic with anxiolytic and antidepressant properties at low doses. Melitracen is a tricyclic antidepressant (TCA). Their synergy is intended for the treatment of mild-to-moderate anxiety, depression, and apathy.
## Primary Indications
* Mild to moderate anxiety.
* Depression (specifically with associated asthenia or apathy).
* Psychosomatic disturbances.
## Adult Dosing
Standard maintenance dose: 1 tablet (0.5 mg flupentixol / 10 mg melitracen) twice daily (morning and noon).
* **Maximum:** 4 tablets daily.
* If insomnia is present: The morning dose can be increased, but the noon dose should be maintained or the medication should be avoided in the late afternoon to prevent sleep disturbance.
## Pediatric Dosing
**Not recommended.** Safety and efficacy have not been established in children or adolescents. Use is generally contraindicated in pediatric populations due to the potential for TCA-related side effects and limited data.
## Dose Adjustments
* **Geriatric:** Use caution; lower starting doses are recommended due to increased sensitivity to anticholinergic effects and risks of orthostatic hypotension.
* **Renal/Hepatic Impairment:** No specific criteria established; individualize therapy based on clinical judgment. Use with extreme caution in severe hepatic impairment, as melitracen is metabolized hepatically.
## Contraindications
* Hypersensitivity to flupentixol or melitracen.
* Myocardial infarction (acute recovery phase).
* Cardiac conduction defects (bundle branch blocks).
* Untreated narrow-angle glaucoma.
* Patients with CNS depression (alcohol, barbiturates, opioid intoxication).
* Blood dyscrasias.
* Concurrent use with MAO inhibitors (must have a 14-day washout period).
## Adverse Effects
* **Common:** Dry mouth, insomnia, dizziness, restlessness, tremors.
* **Anticholinergic:** Blurred vision, constipation, urinary retention, tachycardia.
* **Serious:** Extrapyramidal symptoms (at higher cumulative doses), QT interval prolongation, arrhythmias, seizures, and potential suicide ideation in young adults.
## Key Drug Interactions
* **MAO Inhibitors:** Risk of serotonin syndrome and hypertensive crisis.
* **CNS Depressants:** Potentiation of sedative effects (alcohol, benzodiazepines).
* **Antihypertensives:** Potential for additive hypotension.
* **QT Prolonging Agents:** Increased risk of ventricular arrhythmias.
* **Anticholinergics:** Enhanced anticholinergic toxicity.
## Monitoring
* **Cardiac:** Baseline and periodic ECG, especially in patients with pre-existing heart disease or if approaching maximum doses.
* **Mental Health:** Monitor for worsening depression, suicidal ideation, or behavioral changes, particularly during the initiation of therapy or dose changes.
* **Physical:** Monitor for signs of extrapyramidal symptoms (EPS) and urinary retention.
## Clinical Pearls
* **Activation:** Due to the stimulant nature of the low-dose formulation, avoid evening administration to prevent insomnia.
* **Tapering:** Discontinue gradually to avoid "tricyclic withdrawal" (nausea, headache, irritability).
* **Market Availability:** Availability varies significantly by region (e.g., common in Asia/parts of Europe; not FDA-approved in the US). Always consult local regulatory guidelines for indications.
* **Apathy Focus:** Unique among antidepressant combinations due to the alertness-promoting properties of low-dose flupentixol.
***
**Disclaimer:** This information is for educational purposes only. Drug availability, indications, and dosing protocols may vary by country and local hospital formulary. Always verify with the current local prescribing information, product inserts, or a clinical pharmacist before prescribing or administering medication.
